^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD39 inhibitor

    Related drugs:
    Apply
    Study of SRF617 in Patients With Advanced Solid Tumors (KEYNOTE-A62) (NCT04336098)
    Phase 1
    Coherus Biosciences, Inc.
    Completed
    Last update posted :
    06/04/2024
    Initiation :
    03/16/2020
    Primary completion :
    08/25/2023
    Completion :
    08/25/2023
    HER-2 • PD-L1
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • gemcitabine • albumin-bound paclitaxel • perenostobart (SRF617)
    Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (NCT05891171)
    Phase 1
    Arcus Biosciences, Inc.
    Recruiting
    Last update posted :
    05/24/2024
    Initiation :
    10/13/2023
    Primary completion :
    08/01/2025
    Completion :
    08/01/2025
    HER-2
    |
    HER-2 negative
    |
    carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598
    IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (NCT05742607)
    Phase 2
    Innate Pharma
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    06/23/2023
    Primary completion :
    06/01/2025
    Completion :
    09/01/2026
    EGFR • PD-L1 • ALK
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • IPH5201
    TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers (NCT03884556)
    Phase 1
    Trishula Therapeutics, Inc.
    Completed
    Last update posted :
    10/04/2023
    Initiation :
    04/10/2019
    Primary completion :
    11/30/2022
    Completion :
    09/29/2023
    ENTPD1
    |
    ENTPD1 expression
    |
    Keytruda (pembrolizumab) • gemcitabine • docetaxel • albumin-bound paclitaxel • eltivutabart (TTX-030)
    A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors (NCT05508373)
    Phase 1
    Suzhou Kebo Ruijun Biotechnology Co., Ltd
    Recruiting
    Last update posted :
    08/19/2022
    Initiation :
    03/29/2022
    Primary completion :
    06/15/2024
    Completion :
    08/10/2024
    ENTPD1
    |
    JS019
    A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas (NCT05374226)
    Phase 1
    Suzhou Kebo Ruijun Biotechnology Co., Ltd
    Recruiting
    Last update posted :
    05/16/2022
    Initiation :
    03/31/2022
    Primary completion :
    12/11/2023
    Completion :
    03/07/2024
    ENTPD1
    |
    JS019